Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Monoclonal antibody-based therapy

M von Mehren¹, L M Weiner

¹Fox Chase Cancer Center, Philadelphia, PA 19111, USA.

Current Opinion in Oncology

|November 1, 1996

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Synovial sarcoma: characteristics, challenges, and evolving therapeutic strategies.

ESMO open·2023

Same author

Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib.

Annals of oncology : official journal of the European Society for Medical Oncology·2023

Same author

Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network.

Annals of oncology : official journal of the European Society for Medical Oncology·2020

Same author

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals.

Annals of oncology : official journal of the European Society for Medical Oncology·2019

Same author

Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2018

Same author

Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma.

Oncogene·2016

Monoclonal antibodies are engineered for cancer therapy to target tumor antigens. Advanced strategies enhance antibody delivery, efficacy, and reduce toxicity for improved cancer treatment.

Area of Science:

Oncology
Immunology
Biotechnology

Background:

Monoclonal antibodies (mAbs) are crucial in cancer therapy due to their specific targeting of tumor antigens.
Challenges in antibody delivery and immunogenicity of murine mAbs necessitate advanced engineering strategies.

Purpose of the Study:

To review current advancements in antibody design and delivery for cancer therapy.
To explore novel strategies for enhancing antibody efficacy and reducing toxicity in oncology.

Main Methods:

Protein engineering techniques, including humanization of murine mAbs to reduce immunogenicity.
Conjugation of antibodies to vasoactive substances, liposomes, or radioactive isotopes for improved tumor localization and therapeutic effect.
Development of bispecific antibodies, antibody-superantigen conjugates, and antibody-enzyme conjugates for enhanced immune activation and targeted drug delivery.

Related Experiment Videos

Main Results:

Humanization of murine mAbs minimizes immune responses, enabling repeated dosing.
Antibody conjugates and modified antibody formats demonstrate improved tumor targeting, efficacy, and reduced toxicity.
Emerging strategies like intrabodies target intracellular proteins critical for cancer cell survival.

Conclusions:

Continuous innovation in antibody engineering and delivery systems is vital for overcoming therapeutic challenges in cancer.
Targeting tumor growth factors and enhancing immune cell activation are key areas of antibody-based cancer therapeutics.
Intrabodies represent a promising frontier for targeting intracellular oncogenic proteins.